Incidence and predictors of heart failure among anthracycline-treated older adults with lymphoma

Anthracycline-based chemotherapy is recommended in diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL) but can cause heart failure (HF), especially in older patients who have increased risk due to age and comorbidities. To estimate the risk of incident HF in older DLBCL or cHL patients. Using SEER-Medicare, we identified individuals 65 years of age and older diagnosed with DLBCL or cHL between 2000–2015 who received anthracycline-containing therapy and were free of preexisting HF. Incident HF and HF hospitalization were ascertained from billing codes using validated algorithms. Separate multivariate risk prediction models were developed for the outcomes of 1) incident HF and 2) HF hospitalization using Fine and Gray models that account for the competing risk of death. Among 13,401 individuals with newly diagnosed DLBCL or cHL (mean age 75.1 ± 6.1 years, 49.1% female), we observed 3,343 incident HF diagnoses over a median (IQR) follow-up of 2.7 (0.8, 6.1) years. Two and 5-year estimates of incident HF diagnoses after anthracycline were 14.2% (95% CI 13.6–14.8%) and 21.6% (95% CI 20.9–22.3%), respectively, and 2-year cumulative incidence of HF hospitalization was 9.6% (95% CI 9.1–10.1%) in models accounting for the competing risk of death. Older age, cHL diagnosis, hypertension, diabetes, coronary artery disease, atrial fibrillation, valvular heart disease, chronic obstructive pulmonary disease and peripheral vascular disease were associated with higher incident HF. The optimism-corrected c-statistic was 0.60 (95% CI 0.59, 0.61). Incident HF occurred in more than 14% of older patients with DLBCL or cHL within two years after diagnosis and common cardiac comorbidities predict increased HF risk. Future studies incorporating baseline echocardiographic measures may improve model performance.

Authors

Institutions

Publication Details

Journal
Cardio-Oncology
Published
2026-11-16
DOI
https://doi.org/10.1186/s40959-026-00593-w
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incidence and predictors of heart failure among anthracycline-treated older adults with lymphoma

Susan Kenyon Parsons, David M. Kent, Anita J. Kumar, Jason Nelson et al.
1 links
Cardio-Oncology
Chemotherapy-induced cardiotoxicity and mitigation
article

Incidence and predictors of heart failure among anthracycline-treated older adults with lymphoma

Susan Kenyon Parsons, David M. Kent, Anita J. Kumar, Jason Nelson, Jonathan W. Friedberg, Andrew M. Evens, Jenica N. Upshaw, Bonnie Ky, Cara Guardino, Marvin A Konstam, Angie Mae Rodday, Benjamin Sweigart
article en

Abstract

Anthracycline-based chemotherapy is recommended in diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma (cHL) but can cause heart failure (HF), especially in older patients who have increased risk due to age and comorbidities. To estimate the risk of incident HF in older DLBCL or cHL patients. Using SEER-Medicare, we identified individuals 65 years of age and older diagnosed with DLBCL or cHL between 2000–2015 who received anthracycline-containing therapy and were free of preexisting HF. Incident HF and HF hospitalization were ascertained from billing codes using validated algorithms. Separate multivariate risk prediction models were developed for the outcomes of 1) incident HF and 2) HF hospitalization using Fine and Gray models that account for the competing risk of death. Among 13,401 individuals with newly diagnosed DLBCL or cHL (mean age 75.1 ± 6.1 years, 49.1% female), we observed 3,343 incident HF diagnoses over a median (IQR) follow-up of 2.7 (0.8, 6.1) years. Two and 5-year estimates of incident HF diagnoses after anthracycline were 14.2% (95% CI 13.6–14.8%) and 21.6% (95% CI 20.9–22.3%), respectively, and 2-year cumulative incidence of HF hospitalization was 9.6% (95% CI 9.1–10.1%) in models accounting for the competing risk of death. Older age, cHL diagnosis, hypertension, diabetes, coronary artery disease, atrial fibrillation, valvular heart disease, chronic obstructive pulmonary disease and peripheral vascular disease were associated with higher incident HF. The optimism-corrected c-statistic was 0.60 (95% CI 0.59, 0.61). Incident HF occurred in more than 14% of older patients with DLBCL or cHL within two years after diagnosis and common cardiac comorbidities predict increased HF risk. Future studies incorporating baseline echocardiographic measures may improve model performance.

Cardio-Oncology
Tufts University (US), Tufts Medical Center (US), Beth Israel Deaconess Medical Center (US), University of Rochester Medical Center (US), Deaconess Hospital (US), Rutgers Cancer Institute (US), Tufts Clinical and Translational Science Institute (US), University of Rochester (US), University of Pennsylvania (US)
National Institutes of Health, National Cancer Institute
Good health and well-being
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon